Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET.

Antigens, Surface / metabolism Glutamate Carboxypeptidase II / metabolism Humans Image Processing, Computer-Assisted Lymph Node Excision Male Positron-Emission Tomography Prostatic Neoplasms / diagnostic imaging Salvage Therapy Treatment Failure
PET PSA persistence PSMA prostate cancer salvage lymph node dissection

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
07 2020
Historique:
received: 25 08 2019
accepted: 18 11 2019
pubmed: 7 12 2019
medline: 29 12 2020
entrez: 7 12 2019
Statut: ppublish

Résumé

The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET.

Identifiants

DOI: 10.2967/jnumed.119.235374 PMID: 31806773 PMC: PMC7383079
pubmed: 31806773
pii: jnumed.119.235374
doi: 10.2967/jnumed.119.235374
pmc: PMC7383079
doi:

Substances chimiques

Antigens, Surface 0
FOLH1 protein, human EC 3.4.17.21
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1037-1042

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Strahlenther Onkol. 2015 Apr;191(4):310-20
pubmed: 25326142
Theranostics. 2017 Apr 10;7(6):1770-1780
pubmed: 28529650
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
J Urol. 2019 Dec;202(6):1174-1181
pubmed: 31233369
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
Eur Urol. 2019 Oct;76(4):493-504
pubmed: 30391078
Eur Urol. 2019 Dec;76(6):732-739
pubmed: 31331782
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
Eur Urol. 2019 Apr;75(4):659-666
pubmed: 29625755
J Nucl Med. 2017 Oct;58(10):1617-1623
pubmed: 28408531
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur Urol. 2019 Oct;76(4):517-523
pubmed: 30987843
Eur Urol Focus. 2020 Jan 15;6(1):71-73
pubmed: 30049657
Clin Oncol (R Coll Radiol). 2007 Sep;19(7):542-50
pubmed: 17624745
BJU Int. 2017 Jul;120(1):40-47
pubmed: 27862863
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Cancer Imaging. 2016 Jun 08;16(1):14
pubmed: 27277843
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198

Auteurs

Andrea Farolfi (A)

Nuclear Medicine Unit, University of Bologna, S. Orsola Hospital, Bologna, Italy.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Harun Ilhan (H)

Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.

Andrei Gafita (A)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Francesco Barbato (F)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Manuel Weber (M)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Ali Afshar-Oromieh (A)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.

Fabian Spohn (F)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Axel Wetter (A)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Christoph Rischpler (C)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Boris Hadaschik (B)

Department of Urology, University Hospital Essen, Essen, Germany.

Davide Pianori (D)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; and.

Stefano Fanti (S)

Nuclear Medicine Unit, University of Bologna, S. Orsola Hospital, Bologna, Italy.

Uwe Haberkorn (U)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.

Matthias Eiber (M)

Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Wolfgang Peter Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany wolfgang.fendler@uk-essen.de.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Metalloproteases › Metalloexopeptidases › Glutamate carboxypeptidase II › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Traitement d'image par ordinateur › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Procédures de chirurgie opératoire › Lymphadénectomie › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Thérapeutique › Thérapie de rattrapage › Mapping Prostate Cancer Lesions Before and...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Échec thérapeutique › Mapping Prostate Cancer Lesions Before and...